"We aim to position India as a leader in personalised medicine and drive future innovations"

The landscape of cell and gene therapy (CGT) in India is rapidly evolving, with significant advancements poised to revolutionise patient care.

- 

Priya G Hingorani, Managing Director, Miltenyi Biotech India

At the heart of this transformation is Miltenyi Biotech India, a pioneering force dedicated to bringing cutting-edge technologies and training to the region. In an interaction with BioSpecturm India, Priya G Hingorani, Managing Director of Miltenyi Biotech India, discussed the company's new state-of-the-art innovation and training centre in Genome Valley, Hyderabad, and explored the future of personalised medicine in India. Edited excerpts;

Congratulations on the launch of the Miltenyi Innovation Technology Centre (MITC)! What inspired the creation of this facility at Genome Valley, Hyderabad?

Thank you. Miltenyi Biotech has been pioneering CGT for over 35 years, starting with a small cell separator and growing into a leader in innovation. Recognising India's potential in advanced medical treatments, we saw the need to educate researchers and partners on specialised equipment and evolving therapies.

This led to the establishment of a state-of-the-art training centre in Hyderabad, where scientists from India and beyond can gain hands-on experience. Our goal is to provide comprehensive training, enabling researchers to advance CGT. By offering access to cutting-edge equipment and expertise, we aim to position India as a leader in personalised medicine and drive future innovations in this field.

What new technologies are you bringing to India? Could you elaborate on some of the key technologies that make your centre a leader in CGT?